Department of Engineering of Polymer Materials, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland.
Biomater Sci. 2018 Sep 25;6(10):2552-2565. doi: 10.1039/c8bm00739j.
Chemotherapy still constitutes a basic treatment for various types of cancer. Anthracyclines are effective antineoplastic drugs that are widely used in clinical practice. Unfortunately, they are characterized by high systemic toxicity and lack of tumour selectivity. A promising way to enhance treatment effectiveness and reduce toxicity is the synthesis of systems containing anthracyclines either in the form of complexes for the encapsulation of active drugs or their covalent conjugates with inert carriers. In this respect nanotechnology offers an extensive spectrum of possible solutions. In this review, we discuss recent advances in the development of anthracycline prodrugs based on nanocarriers such as copolymers, lipids, DNA, and inorganic systems. The review focuses on the chemical architecture of the noncovalent nanocarrier-drug systems.
化疗仍然是各种癌症的基本治疗方法。蒽环类抗生素是一种有效的抗肿瘤药物，在临床实践中广泛应用。然而，它们的特点是全身毒性高且缺乏肿瘤选择性。提高治疗效果和降低毒性的一种有前途的方法是合成含有蒽环类抗生素的系统，要么以封装有效药物的复合物的形式，要么以其与惰性载体的共价轭合物的形式。在这方面，纳米技术提供了广泛的可能解决方案。在本文中，我们讨论了基于纳米载体（如共聚物、脂质、DNA 和无机系统）的蒽环类抗生素前药的最新进展。本文重点介绍了非共价纳米载体-药物系统的化学结构。
